Merck's (MRK) KEYTRUDA Receives FDA Breakthrough Therapy Designation from U.S. FDA

Merck (NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with microsatellite instability high (MSI-H) metastatic colorectal cancer. This is the third Breakthrough Therapy Designation granted for KEYTRUDA.
http://www.streetinsider.com/Corporate+News/Mercks+(MRK)+KEYTRUDA+Receives+FDA+Breakthrough+Therapy+Designation+from+U.S.+FDA/11022966.html